HELPER study.

Study name	HELPER study (Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population)
Methods	RCT
Participants	Men and women aged 40‐65 who are invited to participate in the National Cancer Screening Program and receive upper endoscopy
Interventions	10‐day bismuth‐based quadruple therapy (10‐day bismuth‐based quadruple therapy Bismuth 300 mg (4 times a day), lansoprazole 30 mg (twice a day), metronidazole 500 mg (3 times a day), and tetracycline 500 mg (4 times a day) for 10 days) vs placebo
Outcomes	Primary outcome: The incidence of gastric cancer between the intervention and placebo groups [ Time Frame: Up to 10 years After H. pylori eradication ] Secondary outcomes: 1. Incidence of gastric dysplasia 2. Occurrence of adverse events caused by antibiotic treatment 3. Incidence and mortality from other medical conditions such as obesity, diabetes, circulatory diseases, oesophageal diseases as well as other cancers and cognitive impairment 4. Mortality from gastric cancer 5. All‐cause mortality 6. Modification of atrophy score
Starting date	June 2014
Contact information	National Cancer Center, Korea. Il Ju Choi, M.D., Ph.D. +82‐31‐920‐2282 cij1224@ncc.re.kr International Agency for Research on Cancer. Rolando Herrero, M.D., Ph.D. +33 4 72 73 86 83 HerreroR@iarc.fr
Notes	Estimated Study Completion Date: June 2029